Literature DB >> 32647536

Circulating biomarkers for early detection of hepatocellular carcinoma.

Boris J B Beudeker1, Andre Boonstra2.   

Abstract

Hepatocellular carcinoma (HCC) is estimated to be the fourth leading cause of cancer-related deaths worldwide. HCC patients face a dismal prognosis because symptoms usually appear in an advanced stage of disease. The detection of early stage HCC allows for curative surgical treatment and therefore saves lives. Specific non-invasive or diagnostic markers for HCC may represent a valuable tool for detecting these tumors at an early stage. The clinically most established serological biomarker alpha-fetoprotein shows only limited diagnostic performance, however novel candidate biomarkers and biomarker panels for detecting HCC at early stages of development are being studied. In this review we will discuss the findings of these studies.
© The Author(s), 2020.

Entities:  

Keywords:  diagnostics; early biomarkers; early diagnosis; hepatitis B virus; hepatitis C virus; hepatocellular carcinoma; immunology; liquid biopsy; micro RNA; surveillance; viral hepatitis

Year:  2020        PMID： 32647536      PMCID： PMC7325534          DOI： 10.1177/1756284820931734

Source DB:  PubMed          Journal:  Therap Adv Gastroenterol        ISSN： 1756-283X            Impact factor:   4.409


  85 in total

1.  Analysis of Lamin B1, Vimentin and Anti-Ku86 as Prospective Biomarkers of Hepatocellular Carcinoma in Patients with Hepatitis C Virus Infection.

Authors:  Naglaa K Idriss; Michel Fakhry; Hala M Imam; Fatema A Abd-Elmoez; Hossam Abdelewahab; Lobna Abdel-Wahid; Wael A Abbas; Mohamed A A Abozaid; Zain Sayed; Ahmed M Ashmawy
Journal:  Cell Physiol Biochem       Date:  2019

2.  Unique clinical characteristics of patients with hepatocellular carcinoma who present with high plasma des-gamma-carboxy prothrombin and low serum alpha-fetoprotein.

Authors:  K Hamamura; Y Shiratori; S Shiina; M Imamura; S Obi; S Sato; H Yoshida; M Omata
Journal:  Cancer       Date:  2000-04-01       Impact factor: 6.860

3.  Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma.

Authors:  Jian Zhou; Lei Yu; Xue Gao; Jie Hu; Jiping Wang; Zhi Dai; Jie-Fei Wang; Zhiyong Zhang; Shaohua Lu; Xiaowu Huang; Zheng Wang; Shuangjian Qiu; Xiaoying Wang; Guohuan Yang; Huichuan Sun; Zhaoyou Tang; Ying Wu; Hongguang Zhu; Jia Fan
Journal:  J Clin Oncol       Date:  2011-11-21       Impact factor: 44.544

4.  Diagnostic values of alpha-fetoprotein, dickkopf-1, and osteopontin for hepatocellular carcinoma.

Authors:  Tianxiang Ge; Qiujin Shen; Ning Wang; Yurong Zhang; Zhouhong Ge; Wei Chu; Xiufang Lv; Fengbo Zhao; Weifeng Zhao; Jia Fan; Wenxin Qin
Journal:  Med Oncol       Date:  2015-02-06       Impact factor: 3.064

5.  Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases.

Authors:  Xi Chen; Yi Ba; Lijia Ma; Xing Cai; Yuan Yin; Kehui Wang; Jigang Guo; Yujing Zhang; Jiangning Chen; Xing Guo; Qibin Li; Xiaoying Li; Wenjing Wang; Yan Zhang; Jin Wang; Xueyuan Jiang; Yang Xiang; Chen Xu; Pingping Zheng; Juanbin Zhang; Ruiqiang Li; Hongjie Zhang; Xiaobin Shang; Ting Gong; Guang Ning; Jun Wang; Ke Zen; Junfeng Zhang; Chen-Yu Zhang
Journal:  Cell Res       Date:  2008-10       Impact factor: 25.617

6.  Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review.

Authors:  Agostino Colli; Mirella Fraquelli; Giovanni Casazza; Sara Massironi; Alice Colucci; Dario Conte; Piergiorgio Duca
Journal:  Am J Gastroenterol       Date:  2006-03       Impact factor: 10.864

7.  Levels of Cytokines in Serum Associate With Development of Hepatocellular Carcinoma in Patients With HCV Infection Treated With Direct-Acting Antivirals.

Authors:  Jose D Debes; Marjolein van Tilborg; Zwier M A Groothuismink; Bettina E Hansen; Julian Schulze Zur Wiesch; Johann von Felden; Robert J de Knegt; Andre Boonstra
Journal:  Gastroenterology       Date:  2017-11-02       Impact factor: 22.682

8.  GALAD Score for Hepatocellular Carcinoma Detection in Comparison with Liver Ultrasound and Proposal of GALADUS Score.

Authors:  Ju Dong Yang; Benyam D Addissie; Kristin C Mara; William S Harmsen; Jianliang Dai; Ning Zhang; Nicha Wongjarupong; Hawa M Ali; Hamdi A Ali; Fatima A Hassan; Sravanthi Lavu; Jessica L Cvinar; Nasra H Giama; Catherine D Moser; Katsuyuki Miyabe; Loretta K Allotey; Alicia Algeciras-Schimnich; J Paul Theobald; Melissa M Ward; Mindie H Nguyen; Alex S Befeler; K Rajender Reddy; Myron Schwartz; Denise M Harnois; Hiroyuki Yamada; Sudhir Srivastava; Jo Ann Rinaudo; Gregory J Gores; Ziding Feng; Jorge A Marrero; Lewis R Roberts
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-11-21       Impact factor: 4.090

9.  Enhanced circulating transforming growth factor beta 1 is causally associated with an increased risk of hepatocellular carcinoma: a mendelian randomization meta-analysis.

Authors:  Wei-Qun Lu; Ji-Liang Qiu; Zhi-Liang Huang; Hai-Ying Liu
Journal:  Oncotarget       Date:  2016-12-20

10.  Serum Squamous Cell Carcinoma Antigen-Immunoglobulin M complex levels predict survival in patients with cirrhosis.

Authors:  Marco Cagnin; Alessandra Biasiolo; Andrea Martini; Mariagrazia Ruvoletto; Santina Quarta; Silvano Fasolato; Paolo Angeli; Giorgio Fassina; Patrizia Pontisso
Journal:  Sci Rep       Date:  2019-12-27       Impact factor: 4.379
View more
  7 in total

1.  RPLP1 is highly expressed in hepatocellular carcinoma tissues and promotes proliferation, invasion and migration of human hepatocellular carcinoma Hep3b cells.

Authors:  Changji Xie; Kai Cao; Dexin Peng; Lei Qin
Journal:  Exp Ther Med       Date:  2021-05-12       Impact factor: 2.447

Review 2.  Dynamics of m6A RNA Methylome on the Hallmarks of Hepatocellular Carcinoma.

Authors:  Enakshi Sivasudhan; Neil Blake; Zhi-Liang Lu; Jia Meng; Rong Rong
Journal:  Front Cell Dev Biol       Date:  2021-04-01

3.  SPATS2 is positively activated by long noncoding RNA SNHG5 via regulating DNMT3a expression to promote hepatocellular carcinoma progression.

Authors:  Jia Yan; Qing Yu Huang; Ya Jun Huang; Chang Shan Wang; Peng Xia Liu
Journal:  PLoS One       Date:  2022-01-25       Impact factor: 3.240

4.  IL-6 Promoter Hypomethylation Acts As a Diagnostic Biomarker in Hepatitis B Virus-Associated Hepatocellular Carcinoma.

Authors:  Jie-Ru Yang; Ju Wang; Hai-Ming Li; Shuai Gao; Yu-Chen Fan; Kai Wang
Journal:  Front Oncol       Date:  2022-03-11       Impact factor: 6.244

5.  Serine Protease Inhibitor Kazal Type 1, A Potential Biomarker for the Early Detection, Targeting, and Prediction of Response to Immune Checkpoint Blockade Therapies in Hepatocellular Carcinoma.

Authors:  Jianlong Jia; Latai Ga; Yang Liu; Zhiyi Yang; Yue Wang; Xuanze Guo; Ruichen Ma; Ruonan Liu; Tianyou Li; Zeyao Tang; Jun Wang
Journal:  Front Immunol       Date:  2022-07-18       Impact factor: 8.786

6.  A Serum Metabolite Classifier for the Early Detection of Type 2 Diabetes Mellitus-Positive Hepatocellular Cancer.

Authors:  Lin-Lin Cao; Yi Han; Lin Pei; Zhi-Hong Yue; Bo-Yu Liu; Jing-Wen Cui; Mei Jia; Hui Wang
Journal:  Metabolites       Date:  2022-07-01

7.  Circulating Cytokines Reflect the Etiology-Specific Immune Environment in Cirrhosis and HCC.

Authors:  Boris J B Beudeker; Zwier M A Groothuismink; Annemiek A van der Eijk; Jose D Debes; Andre Boonstra
Journal:  Cancers (Basel)       Date:  2022-10-07       Impact factor: 6.575
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.